- Home
- QS vs BBIO Comparison
QS vs BBIO Comparison
Compare QS & BBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- QS
- BBIO
- Stock Information
- Founded
- QS 2010
- BBIO 2015
- Country
- QS United States
- BBIO United States
- Employees
- QS N/A
- BBIO N/A
- Industry
- QS Auto Parts:O.E.M.
- BBIO Biotechnology: Pharmaceutical Preparations
- Sector
- QS Consumer Discretionary
- BBIO Health Care
- Exchange
- QS Nasdaq
- BBIO Nasdaq
- Market Cap
- QS 8.8B
- BBIO 10.4B
- IPO Year
- QS N/A
- BBIO 2019
- Fundamental
- Price
- QS $11.80
- BBIO $65.30
- Analyst Decision
- QS Sell
- BBIO Strong Buy
- Analyst Count
- QS 7
- BBIO 19
- Target Price
- QS $8.07
- BBIO $74.79
- AVG Volume (30 Days)
- QS 38.2M
- BBIO 2.9M
- Earning Date
- QS 10-22-2025
- BBIO 10-29-2025
- Dividend Yield
- QS N/A
- BBIO N/A
- EPS Growth
- QS N/A
- BBIO N/A
- EPS
- QS N/A
- BBIO N/A
- Revenue
- QS N/A
- BBIO $353,780,000.00
- Revenue This Year
- QS N/A
- BBIO $123.32
- Revenue Next Year
- QS N/A
- BBIO $73.46
- P/E Ratio
- QS N/A
- BBIO N/A
- Revenue Growth
- QS N/A
- BBIO 62.46
- 52 Week Low
- QS $3.40
- BBIO $22.05
- 52 Week High
- QS $19.07
- BBIO $69.48
- Technical
- Relative Strength Index (RSI)
- QS 36.79
- BBIO 60.21
- Support Level
- QS $14.84
- BBIO $64.34
- Resistance Level
- QS $16.22
- BBIO $67.71
- Average True Range (ATR)
- QS 1.44
- BBIO 2.56
- MACD
- QS -0.57
- BBIO -0.16
- Stochastic Oscillator
- QS 0.16
- BBIO 62.21
About QS QuantumScape Corporation
QuantumScape Corp is engaged in the development of next-generation solid-state lithium-metal batteries for use in electric vehicles and other applications. The company's solid-state lithium-metal battery technology is designed to offer greater energy density, faster charging, and enhanced safety. Its battery cells have none of the host materials used in conventional anodes.
About BBIO BridgeBio Pharma Inc.
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis) , is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.